Physician profile
Vinay K Kumar
NPI 1184616849
$7,787.97
in general payments reported to CMS, 2019-2025
47 companies · $850 in 2025
The $850 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $834 · 2021: $1,497 · 2022: $1,380 · 2023: $1,437 · 2024: $1,059 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,346.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,464.07 | 2021-2025 | |
| Novo Nordisk INC | $842.68 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $565.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $565.23 | 2019-2025 | Breztri, Farxiga, Evusheld |
| Glaxosmithkline, LLC. | $435.26 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $319.42 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $316.82 | 2019-2024 | Xarelto, Spravato |
| Pfizer INC. | $304.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $297.14 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $277.04 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.87 | 2019-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Amgen INC. | $223.72 | 2021-2025 | Otezla, Repatha, Repatha |
| Phathom Pharmaceuticals, INC. | $161.54 | 2024-2025 | Voquezna |
| Allergan, INC. | $144.17 | 2019-2021 | |
| Abbott Laboratories | $133.66 | 2022-2025 | Freestyle Libre 3, Proclaim |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.